Neurenati Therapeutics Welcomes Dr Daniel Guay to Its Board of Directors and Dr Carlo Di Lorenzo to Its Scientific and Clinical Advisory Board
Neurenati Therapeutics, a biotech company focused on the development of therapies for rare diseases, is pleased to appoint two highly-experienced members to its Board of Directors and Scientific and Clinical Advisory Board.
The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease
Neurenati Therapeutics Inc., a biotech company focused on rare pediatric diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to NEU-001, a novel combination therapy utilizing a neurotrophic growth factor, for the treatment of Hirschsprung disease (HD).
